Business Daily Media

Business Marketing

.

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

  • Written by ACN Newswire - Press Releases

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of

Read more //?#

Popular

TradieSpec Announces National Expansion

TradieSpec, a Sydney-based ute-hire startup, is set to open its doors in Brisbane and Melbourne after unrivalled demand for its tradie-friendly vehicle finance model. In response to an unprecedented surge in demand for trade-...

5 Best Sales Team Management Strategies For Sales Managers

The sales team of any company is an essential part of the organisation's growth, as they need to acquire new clients and keep them happy with the service and products they receive. With such a vital role for business, the team...

CA ANZ responds to recent release of FASEA reforms

Chartered Accountants Australia and New Zealand (CA ANZ) welcomes the release of the Financial Adviser Standards and Ethics Authority’s (FASEA’s) draft legislation for five out of the seven standards.   With the next round of ...

Virtual Office
Tomorrow Business Growth